| 1 |
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005,55(2):74-108.
|
| 2 |
Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials[J]. Radiology,2002,224(1):47-54.
|
| 3 |
Takayasu K, Arii S, Ikai I, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis[J]. AJR Am J Roentgenol, 2010,194(3):830-837.
|
| 4 |
Yamakado K, Miyayama S, Hirota S, et al. Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis[J]? Jpn J Radiol, 2012,30(7):560-566.
|
| 5 |
Matsui O, Miyayama S, Sanada J, et al. Interventional oncology: new options for interstitial treatments and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome[J]. J Hepatobiliary Pancreat Sci, 2010,17(4):407-409.
|
| 6 |
Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2010,33(3):541-551.
|
| 7 |
Liang B, Xiong F, Wu H, et al. Effect of transcatheter intraarterial therapies on the distribution of doxorubicin in liver cancer in a rabbit model[J]. Plus One,2013,8(10):e76388.
|
| 8 |
Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design[J]. J Hepatol,2012,56(6):1330-1335.
|
| 9 |
Ikeda M, Arai Y, Park SJ, et al. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: An Asian cooperative study between Japan and Korea[J]. J Vasc Interv Radiol,2013,24(4):490-500.
|
| 10 |
Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study[J]. Cardiovasc Intervent Radiol，2010，33(1):41-52.
|
| 11 |
Golfieri R, Giampalma E, Renzulli M, et al. Randomized controlled trial of doxorubicin-eluting beads vs conventionalchemoembolisation for hepatocellular carcinoma[J]. Br J Cancer,2014,111(2):255-264.
|
| 12 |
Namur J, Citron SJ, Sellers MT, et al. Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentrat-ion and distribution in patient liver explants[J]. J Hepatol, 2011,55(6):1332-1338.
|